P58 The use of a multi-analyte immunoassay panel (MAIP) to detect potential prognostic biomarkers associated with 2-month progression free survival rate in patients treated with Enzastaurin as 2nd and 3rd line therapy of NSCLC
Year: 2007
Type: conference-abstract
Authors: A. Cleverly, G. Bepler, Y. Oh, H. Burris, R.S. Herbst, M. Lahn
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2013111506